

PERFORMANCE UPDATE 9M 2025

PT Phapros Tbk

Document of **Corporate Secretary**
PT Phapros Tbk



01



Company Overview




IDR 683,6 Billion

9M 2025 Revenue +19,5% yoy



IDR 7,7 Billion

9M 2025 Net Income for the Period 111,2% yoy




5 Products Launched

(published as of September 2025)

- Established in **1954** with more than **250 products** available in the market
- **Antimo** continues to be **the market leader** among competitors, dominating over **70% market share** in Antiemetic & Anti-Nausea treatment
- One of few Pharmaceutical Manufacturing Industries with **Certified Calibration Laboratory**

Shareholder Composition



Phapros' Leading Products



Antimo Group



Tablet Tambah Darah



Dexamine



Livron B Plex



Omeprazole



Pro TB Group



Noza



Dexamethasone



Pehacain




02



Market Overview

Indonesia Economic Outlook

GDP Growth Projection for 2025



4,8 – 5,0%



World Bank : 5%



OECD : 5%



IMF : 4,8 – 4,9%



ADB : 5,0%

Economic growth in Indonesia is expected to remain resilient in 2025 supported by robust domestic demand, investment growth, and accommodative fiscal and monetary policies.

A close-up photograph of a variety of pharmaceuticals, including white, yellow, blue, pink, and orange pills and capsules, scattered on a light surface.

03




Performance Highlight

Corporate Event Highlights



The awards received highlight Phapros' strong performance in governance, risk and compliance, as well as operational safety excellence, demonstrating a solid foundation for sustainable long-term growth.

Financial Update



Following the turnaround in 1H 2025, the Company further accelerated its performance in 9M 2025, driven by stronger revenue, improved net income, and substantial EBITDA growth.

04

Business Strategy

GRAND STRATEGY 2025

Sustainable Financial Capability

Strengthening Working Capital

Cost Control

Customer Satisfaction Enhancement

Customer Satisfaction Index

Product Portfolio & Business Improvement

Enhancing Product Portfolio & New Products

Business Expansion

Business Process & System Transformation

Increasing Market Share

Smart Supply Chain with an Integrated Database

Innovation Development

Digital Transformation

COGS Optimization

Regulatory Compliance

Human Resources & Culture Optimization

Organizational Restructuring

Human Capital Cost-Effectiveness Ratio

Human Capital Capacity Development


Terima Kasih

Semoga Sehat Selalu



KANTOR PUSAT

Menara Rajawali Lantai 17
JL. DR Ide Anak Agung Gde Agung
Mega Kuningan JAKARTA 12950 INDONESIA
Phone : +62 21 576 2709 | Fax : +62 21 576 3910



PABRIK

Jl. Simongan No 131
Semarang 50148 INDONESIA
Phone : (62-24) 762 5484